Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPH 1101

Drug Profile

IPH 1101

Alternative Names: IPH-1101; Phosphostim

Latest Information Update: 21 Mar 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INSERM
  • Developer Innate Pharma
  • Class Antineoplastics; Phosphoric acid esters; Small molecules
  • Mechanism of Action Cytokine stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer

Highest Development Phases

  • Discontinued Chronic myeloid leukaemia; Follicular lymphoma; Hepatitis C; Malignant melanoma; Renal cancer

Most Recent Events

  • 14 Jun 2010 Discontinued - Phase-II for Malignant melanoma in Belgium (IV)
  • 14 Jun 2010 Discontinued - Phase-II for Malignant melanoma in France (IV)
  • 14 Jun 2010 Discontinued - Phase-II for Malignant melanoma in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top